Standard
Discovery of TUG-770. / Christiansen, Elisabeth; Hansen, Steffen Vissing Fahnøe; Urban, Christian; Hudson, Brian D; Wargent, Edward T; Grundmann, Manuel; Jenkins, Laura; Zaibi, Mohamed; Stocker, Claire J; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U; Milligan, Graeme; Cawthorne, Michael A; Ulven, Trond.
In:
A C S Medicinal Chemistry Letters, Vol. 4, No. 5, 09.05.2013, p. 441-445.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Christiansen, E, Hansen, SVF, Urban, C, Hudson, BD, Wargent, ET, Grundmann, M, Jenkins, L, Zaibi, M, Stocker, CJ, Ullrich, S, Kostenis, E, Kassack, MU, Milligan, G, Cawthorne, MA
& Ulven, T 2013, '
Discovery of TUG-770',
A C S Medicinal Chemistry Letters, vol. 4, no. 5, pp. 441-445.
https://doi.org/10.1021/ml4000673
APA
Christiansen, E., Hansen, S. V. F., Urban, C., Hudson, B. D., Wargent, E. T., Grundmann, M., Jenkins, L., Zaibi, M., Stocker, C. J., Ullrich, S., Kostenis, E., Kassack, M. U., Milligan, G., Cawthorne, M. A.
, & Ulven, T. (2013).
Discovery of TUG-770.
A C S Medicinal Chemistry Letters,
4(5), 441-445.
https://doi.org/10.1021/ml4000673
Vancouver
Christiansen E, Hansen SVF, Urban C, Hudson BD, Wargent ET, Grundmann M et al.
Discovery of TUG-770.
A C S Medicinal Chemistry Letters. 2013 May 9;4(5):441-445.
https://doi.org/10.1021/ml4000673
Author
Christiansen, Elisabeth ; Hansen, Steffen Vissing Fahnøe ; Urban, Christian ; Hudson, Brian D ; Wargent, Edward T ; Grundmann, Manuel ; Jenkins, Laura ; Zaibi, Mohamed ; Stocker, Claire J ; Ullrich, Susanne ; Kostenis, Evi ; Kassack, Matthias U ; Milligan, Graeme ; Cawthorne, Michael A ; Ulven, Trond. / Discovery of TUG-770. In: A C S Medicinal Chemistry Letters. 2013 ; Vol. 4, No. 5. pp. 441-445.
Bibtex
@article{45585a2d6270406aa0fc6af0aadc772a,
title = "Discovery of TUG-770",
abstract = "Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes. We here report the discovery of a highly potent FFA1 agonist with favorable physicochemical and pharmacokinetic properties. The compound efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.",
author = "Elisabeth Christiansen and Hansen, {Steffen Vissing Fahn{\o}e} and Christian Urban and Hudson, {Brian D} and Wargent, {Edward T} and Manuel Grundmann and Laura Jenkins and Mohamed Zaibi and Stocker, {Claire J} and Susanne Ullrich and Evi Kostenis and Kassack, {Matthias U} and Graeme Milligan and Cawthorne, {Michael A} and Trond Ulven",
year = "2013",
month = may,
day = "9",
doi = "10.1021/ml4000673",
language = "English",
volume = "4",
pages = "441--445",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "5",
}
RIS
TY - JOUR
T1 - Discovery of TUG-770
AU - Christiansen, Elisabeth
AU - Hansen, Steffen Vissing Fahnøe
AU - Urban, Christian
AU - Hudson, Brian D
AU - Wargent, Edward T
AU - Grundmann, Manuel
AU - Jenkins, Laura
AU - Zaibi, Mohamed
AU - Stocker, Claire J
AU - Ullrich, Susanne
AU - Kostenis, Evi
AU - Kassack, Matthias U
AU - Milligan, Graeme
AU - Cawthorne, Michael A
AU - Ulven, Trond
PY - 2013/5/9
Y1 - 2013/5/9
N2 - Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes. We here report the discovery of a highly potent FFA1 agonist with favorable physicochemical and pharmacokinetic properties. The compound efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.
AB - Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes. We here report the discovery of a highly potent FFA1 agonist with favorable physicochemical and pharmacokinetic properties. The compound efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.
U2 - 10.1021/ml4000673
DO - 10.1021/ml4000673
M3 - Journal article
VL - 4
SP - 441
EP - 445
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
SN - 1948-5875
IS - 5
ER -
